It also highlights the rare metastatic behavior of IDH-mutant astrocytomas (previously classified as secondary glioblastomas) and emphasizes the need for long-term monitoring and individualized treatment strategies to improve outcomes. The gene discussed is IDH1; the disease is glioblastoma.